Humana Competitors

Abbott Laboratories (NYSE:ABT) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Valuation & Earnings

This table compares Abbott Laboratories and Humana's top-line revenue, earnings per share and valuation.

Abbott Laboratories has higher earnings, but lower revenue than Humana. Humana is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Abbott Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Abbott Laboratories and Humana, as provided by MarketBeat.com.

Abbott Laboratories presently has a consensus price target of $121.8333, suggesting a potential upside of 5.36%. Humana has a consensus price target of $462.10, suggesting a potential upside of 15.22%. Given Humana's higher possible upside, analysts plainly believe Humana is more favorable than Abbott Laboratories.

Profitability

This table compares Abbott Laboratories and Humana's net margins, return on equity and return on assets.

Dividends

Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.6%. Humana pays an annual dividend of $2.50 per share and has a dividend yield of 0.6%. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. Humana pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has increased its dividend for 49 consecutive years and Humana has increased its dividend for 4 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider and Institutional Ownership

72.6% of Abbott Laboratories shares are held by institutional investors. Comparatively, 91.9% of Humana shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 0.4% of Humana shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Abbott Laboratories beats Humana on 9 of the 17 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Volatility & Risk

Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.

Dividends

Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.6%. Humana pays an annual dividend of $2.50 per share and has a dividend yield of 0.6%. Eli Lilly and pays out 56.3% of its earnings in the form of a dividend. Humana pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has increased its dividend for 1 consecutive years and Humana has increased its dividend for 4 consecutive years.

Valuation & Earnings

This table compares Eli Lilly and and Humana's top-line revenue, earnings per share and valuation.

Eli Lilly and has higher earnings, but lower revenue than Humana. Humana is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

75.6% of Eli Lilly and shares are held by institutional investors. Comparatively, 91.9% of Humana shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Comparatively, 0.4% of Humana shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Eli Lilly and and Humana's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for Eli Lilly and and Humana, as provided by MarketBeat.com.

Eli Lilly and presently has a consensus price target of $192.60, suggesting a potential downside of 6.97%. Humana has a consensus price target of $462.10, suggesting a potential upside of 15.22%. Given Humana's higher possible upside, analysts plainly believe Humana is more favorable than Eli Lilly and.

Novartis (NYSE:NVS) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Risk and Volatility

Novartis has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Dividends

Novartis pays an annual dividend of $2.20 per share and has a dividend yield of 2.6%. Humana pays an annual dividend of $2.50 per share and has a dividend yield of 0.6%. Novartis pays out 42.0% of its earnings in the form of a dividend. Humana pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has increased its dividend for 1 consecutive years and Humana has increased its dividend for 4 consecutive years.

Valuation and Earnings

This table compares Novartis and Humana's top-line revenue, earnings per share and valuation.

Novartis has higher earnings, but lower revenue than Humana. Novartis is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

9.9% of Novartis shares are owned by institutional investors. Comparatively, 91.9% of Humana shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 0.4% of Humana shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Novartis and Humana's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Novartis and Humana, as provided by MarketBeat.com.

Novartis presently has a consensus target price of $111.00, suggesting a potential upside of 32.57%. Humana has a consensus target price of $462.10, suggesting a potential upside of 15.22%. Given Novartis' higher possible upside, equities research analysts clearly believe Novartis is more favorable than Humana.

Summary

Humana beats Novartis on 9 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Risk and Volatility

Pfizer has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.5%. Humana pays an annual dividend of $2.50 per share and has a dividend yield of 0.6%. Pfizer pays out 52.9% of its earnings in the form of a dividend. Humana pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 1 consecutive years and Humana has increased its dividend for 4 consecutive years.

Valuation and Earnings

This table compares Pfizer and Humana's top-line revenue, earnings per share and valuation.

Pfizer has higher earnings, but lower revenue than Humana. Pfizer is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 91.9% of Humana shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 0.4% of Humana shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Pfizer and Humana's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Pfizer and Humana, as provided by MarketBeat.com.

Pfizer presently has a consensus target price of $39.5333, suggesting a potential upside of 15.09%. Humana has a consensus target price of $462.10, suggesting a potential upside of 15.22%. Given Humana's stronger consensus rating and higher possible upside, analysts clearly believe Humana is more favorable than Pfizer.

Summary

Humana beats Pfizer on 10 of the 17 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Risk and Volatility

Merck & Co., Inc. has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.5%. Humana pays an annual dividend of $2.50 per share and has a dividend yield of 0.6%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Humana pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Humana has increased its dividend for 4 consecutive years.

Valuation and Earnings

This table compares Merck & Co., Inc. and Humana's top-line revenue, earnings per share and valuation.

Merck & Co., Inc. has higher earnings, but lower revenue than Humana. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

72.9% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 91.9% of Humana shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 0.4% of Humana shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Merck & Co., Inc. and Humana's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Merck & Co., Inc. and Humana, as provided by MarketBeat.com.

Merck & Co., Inc. presently has a consensus target price of $95.3571, suggesting a potential upside of 28.57%. Humana has a consensus target price of $462.10, suggesting a potential upside of 15.22%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, equities research analysts clearly believe Merck & Co., Inc. is more favorable than Humana.

Summary

Merck & Co., Inc. beats Humana on 9 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Risk and Volatility

AbbVie has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Insider and Institutional Ownership

67.5% of AbbVie shares are owned by institutional investors. Comparatively, 91.9% of Humana shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.4% of Humana shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares AbbVie and Humana's net margins, return on equity and return on assets.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.9%. Humana pays an annual dividend of $2.50 per share and has a dividend yield of 0.6%. AbbVie pays out 58.2% of its earnings in the form of a dividend. Humana pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 49 consecutive years and Humana has increased its dividend for 4 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for AbbVie and Humana, as provided by MarketBeat.com.

AbbVie presently has a consensus target price of $115.50, suggesting a potential upside of 8.85%. Humana has a consensus target price of $462.10, suggesting a potential upside of 15.22%. Given Humana's stronger consensus rating and higher possible upside, analysts clearly believe Humana is more favorable than AbbVie.

Valuation and Earnings

This table compares AbbVie and Humana's top-line revenue, earnings per share and valuation.

AbbVie has higher earnings, but lower revenue than Humana. AbbVie is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.